Compare Amphastar Pharmaceuticals Inc (AMPH) vs MakeMyTrip Ltd (MMYT) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

MMYT trades at $58.62, up 1.03% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.25 exceeding expectations. Revenue reached $978.34 million in 2025, though net income margin is projected to narrow to 4.96% in 2026. Analyst consensus is strongly positive with 72.73% buy ratings. Recent news highlights temporary travel disruptions but maintains confidence in long-term growth.

The outlook remains favorable given consistent earnings outperformance and robust analyst support, but risks include projected margin compression and rising debt levels. Investors should weigh strong operational cash flow against potential volatility from travel industry headwinds and increasing liabilities in the coming year.